-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Downgrades Foghorn Therapeutics to Neutral, Lowers Price Target to $2

Benzinga·10/02/2026 14:45:53
語音播報
Wedbush analyst Robert Driscoll downgrades Foghorn Therapeutics (NASDAQ:FHTX) from Outperform to Neutral and lowers the price target from $10 to $2.